{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T02:51:25Z","timestamp":1770432685904,"version":"3.49.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Project of Invigorating Health Care through Science, Technology and Education, Jiangsu Provincial Key Medical Discipline Cultivation Unit","award":["No.JSDW202250"],"award-info":[{"award-number":["No.JSDW202250"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No.22474058"],"award-info":[{"award-number":["No.22474058"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100018531","name":"Major Science and Technology Projects in Yunnan Province","doi-asserted-by":"publisher","award":["202403AC100006"],"award-info":[{"award-number":["202403AC100006"]}],"id":[{"id":"10.13039\/501100018531","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Microbiol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00284-025-04646-8","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T10:30:58Z","timestamp":1765362658000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Synergistic Antibacterial Effects of Ceftazidime\/Avibactam and Auranofin Combination against Carbapenem-Resistant Klebsiella pneumoniae: In Vitro and in Vivo Evaluation"],"prefix":"10.1007","volume":"83","author":[{"given":"Lingfei","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunge","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijie","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunlong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guohua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuejiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7795-3422","authenticated-orcid":false,"given":"Haiping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"issue":"10459","key":"4646_CR1","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","volume":"404","author":"M Naghavi","year":"2024","unstructured":"Naghavi M, Vollset SE, Ikuta KS et al (2024) Global burden of bacterial antimicrobial resistance 1990\u20132021: a systematic analysis with forecasts to 2050. Lancet 404(10459):1199\u20131226","journal-title":"Lancet"},{"key":"4646_CR2","unstructured":"World Health Organization (2024) WHO updates list of drug-resistant bacteria most threatening to human health. Available from: https:\/\/www.who.int\/news-room\/detail\/17-05-2024-updated-list [Accessed 17 May 2024] [EB\/OL]"},{"issue":"3","key":"4646_CR3","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/s41564-024-01612-1","volume":"9","author":"F Hu","year":"2024","unstructured":"Hu F, Pan Y, Li H et al (2024) Carbapenem-resistant Klebsiella pneumoniae capsular types, antibiotic resistance and virulence factors in China: a longitudinal, multi-centre study. Nat Microbiol 9(3):814\u2013829","journal-title":"Nat Microbiol"},{"issue":"7","key":"4646_CR4","doi-asserted-by":"publisher","first-page":"e169","DOI":"10.1093\/cid\/ciaa1478","volume":"72","author":"PD Tamma","year":"2021","unstructured":"Tamma PD, Aitken SL, Bonomo RA et al (2021) Infectious diseases society of America guidance on the treatment of Extended-Spectrum beta-lactamase producing enterobacterales (ESBL-E), Carbapenem-Resistant enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat resistance (DTR-P. aeruginosa)[J]. Clin Infect Dis 72(7):e169\u2013e183","journal-title":"Clin Infect Dis"},{"issue":"1","key":"4646_CR5","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s10096-020-04000-9","volume":"40","author":"I Galani","year":"2021","unstructured":"Galani I, Karaiskos I, Angelidis E et al (2021) Emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in KPC-2-producing Klebsiella pneumoniae of sequence type 39 during treatment. Eur J Clin Microbiol Infect Dis 40(1):219\u2013224","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"10","key":"4646_CR6","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1093\/jac\/dkaa241","volume":"75","author":"L Sun","year":"2020","unstructured":"Sun L, Chen W, Li H et al (2020) Phenotypic and genotypic analysis of KPC-51 and KPC-52, two novel KPC-2 variants conferring resistance to ceftazidime\/avibactam in the KPC-producing Klebsiella pneumoniae ST11 clone background. J Antimicrob Chemother 75(10):3072\u20133074","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"4646_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.09.020","volume":"55","author":"P Gaibani","year":"2020","unstructured":"Gaibani P, Ambretti S, Campoli C et al (2020) Genomic characterization of a Klebsiella pneumoniae ST1519 resistant to ceftazidime\/avibactam carrying a novel KPC variant (KPC-36). Int J Antimicrob Agents 55(1):105816","journal-title":"Int J Antimicrob Agents"},{"key":"4646_CR8","doi-asserted-by":"crossref","unstructured":"Munoz-Price LS, Reeme AE, Buchan BW et al (2019) Patient-to-Patient transmission of Klebsiella pneumoniae carbapenemase variants with reduced Ceftazidime-Avibactam Susceptibility[J]. Antimicrob Agents Chemother, 63(10) :e00955-19","DOI":"10.1128\/AAC.00955-19"},{"issue":"7","key":"4646_CR9","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/j.drudis.2022.02.010","volume":"27","author":"Y Liu","year":"2022","unstructured":"Liu Y, Lu Y, Xu Z et al (2022) Repurposing of the gold drug auranofin and a review of its derivatives as antibacterial therapeutics. Drug Discov Today 27(7):1961\u20131973","journal-title":"Drug Discov Today"},{"issue":"2","key":"4646_CR10","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1016\/S1473-3099(18)30513-9","volume":"19","author":"U Theuretzbacher","year":"2019","unstructured":"Theuretzbacher U, Gottwalt S, Beyer P et al (2019) Analysis of the clinical antibacterial and antituberculosis pipeline. Lancet Infect Dis 19(2):e40\u2013e50","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"4646_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-26674-0","volume":"8","author":"A AbdelKhalek","year":"2018","unstructured":"AbdelKhalek A, Abutaleb NS, Elmagarmid KA et al (2018) Repurposing auranofin as an intestinal decolonizing agent for vancomycin-resistant enterococci. Sci Rep 8(1):8353","journal-title":"Sci Rep"},{"issue":"9","key":"4646_CR12","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1093\/jac\/dkv163","volume":"70","author":"L Aguinagalde","year":"2015","unstructured":"Aguinagalde L, Diez-Martinez R, Yuste J et al (2015) Auranofin efficacy against MDR Streptococcus pneumoniae and Staphylococcus aureus infections. J Antimicrob Chemother 70(9):2608\u20132617","journal-title":"J Antimicrob Chemother"},{"issue":"14","key":"4646_CR13","doi-asserted-by":"publisher","first-page":"4453","DOI":"10.1073\/pnas.1504022112","volume":"112","author":"MB Harbut","year":"2015","unstructured":"Harbut MB, Vilcheze C, Luo X et al (2015) Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis. Proc Natl Acad Sci U S A 112(14):4453\u20134458","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"4646_CR14","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.4155\/fmc-2018-0544","volume":"11","author":"N Tharmalingam","year":"2019","unstructured":"Tharmalingam N, Ribeiro NQ, Da SD et al (2019) Auranofin is an effective agent against clinical isolates of Staphylococcus aureus[J]. Future Med Chem 11(12):1417\u20131425","journal-title":"Future Med Chem"},{"key":"4646_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.02541","volume":"9","author":"NS Torres","year":"2018","unstructured":"Torres NS, Montelongo-Jauregui D, Abercrombie JJ et al (2018) Antimicrobial and antibiofilm activity of synergistic combinations of a commercially available small compound library with colistin against Pseudomonas aeruginosa. Front Microbiol 9:2541","journal-title":"Front Microbiol"},{"issue":"11","key":"4646_CR16","volume":"5","author":"W Sun","year":"2016","unstructured":"Sun W, Weingarten RA, Xu M et al (2016) Rapid antimicrobial susceptibility test for identification of new therapeutics and drug combinations against multidrug-resistant bacteria. Emerg Microbes Infect 5(11):e116","journal-title":"Emerg Microbes Infect"},{"issue":"1","key":"4646_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18939-y","volume":"11","author":"H Sun","year":"2020","unstructured":"Sun H, Zhang Q, Wang R et al (2020) Resensitizing carbapenem- and colistin-resistant bacteria to antibiotics using auranofin. Nat Commun 11(1):5263","journal-title":"Nat Commun"},{"key":"4646_CR18","volume-title":"Performance standards for antimicrobial susceptibility testing: 34th edition M100-ED34","author":"Clinical and Laboratory Standards Institute","year":"2024","unstructured":"Clinical and Laboratory Standards Institute (2024) Performance standards for antimicrobial susceptibility testing: 34th edition M100-ED34. CLSI, Wayne, PA, USA"},{"key":"4646_CR19","doi-asserted-by":"crossref","unstructured":"Lin YW, Yu HH, Zhao J et al (2018) Polymyxin B in combination with Enrofloxacin exerts synergistic killing against extensively Drug-Resistant Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother, 62(6):e00028-18","DOI":"10.1128\/AAC.00028-18"},{"issue":"1","key":"4646_CR20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.diagmicrobio.2010.12.002","volume":"70","author":"L Poirel","year":"2011","unstructured":"Poirel L, Walsh TR, Cuvillier V et al (2011) Multiplex PCR for detection of acquired carbapenemase genes[J]. Diagn Microbiol Infect Dis 70(1):119\u2013123","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"6","key":"4646_CR21","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1128\/JCM.40.6.2153-2162.2002","volume":"40","author":"FJ Perez-Perez","year":"2002","unstructured":"Perez-Perez FJ, Hanson ND (2002) Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR[J]. J Clin Microbiol 40(6):2153\u20132162","journal-title":"J Clin Microbiol"},{"issue":"12","key":"4646_CR22","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1128\/AAC.47.12.3724-3732.2003","volume":"47","author":"M Edelstein","year":"2003","unstructured":"Edelstein M, Pimkin M, Palagin I et al (2003) Prevalence and molecular epidemiology of CTX-M extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Russian hospitals[J]. Antimicrob Agents Chemother 47(12):3724\u20133732","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"4646_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jinf.2006.01.014","volume":"54","author":"Y Yu","year":"2007","unstructured":"Yu Y, Ji S, Chen Y et al (2007) Resistance of strains producing extended-spectrum beta-lactamases and genotype distribution in China[J]. J Infect 54(1):53\u201357","journal-title":"J Infect"},{"issue":"3","key":"4646_CR24","doi-asserted-by":"publisher","first-page":"e123121","DOI":"10.1128\/Spectrum.01231-21","volume":"9","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Lin Y, Zhang X et al (2021) Combining colistin with furanone C-30 rescues colistin resistance of Gram-Negative bacteria in vitro and in Vivo[J]. Microbiol Spectr 9(3):e123121","journal-title":"Microbiol Spectr"},{"issue":"1","key":"4646_CR25","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41467-018-02875-z","volume":"9","author":"CR MacNair","year":"2018","unstructured":"MacNair CR, Stokes JM, Carfrae LA et al (2018) Overcoming mcr-1 mediated colistin resistance with colistin in combination with other antibiotics[J]. Nat Commun 9(1):458","journal-title":"Nat Commun"},{"issue":"1","key":"4646_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkg301","volume":"52","author":"FC Odds","year":"2003","unstructured":"Odds FC (2003) Synergy, antagonism, and what the chequerboard puts between them[J]. J Antimicrob Chemother 52(1):1","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"4646_CR27","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ejvs.2015.10.016","volume":"51","author":"X Berard","year":"2016","unstructured":"Berard X, Stecken L, Pinaquy JB et al (2016) Comparison of the antimicrobial properties of silver impregnated vascular grafts with and without Triclosan[J]. Eur J Vasc Endovasc Surg 51(2):285\u2013292","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"2","key":"4646_CR28","doi-asserted-by":"publisher","first-page":"e405222","DOI":"10.1128\/spectrum.04052-22","volume":"11","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Han Y, Wang L et al (2023) Flufenamic Acid, a promising agent for the sensitization of Colistin-Resistant Gram-Negative bacteria to Colistin[J]. Microbiol Spectr 11(2):e405222","journal-title":"Microbiol Spectr"},{"key":"4646_CR29","doi-asserted-by":"crossref","unstructured":"Domalaon R, De Silva PM, Kumar A et al (2019) The Anthelmintic Drug Niclosamide Synergizes with Colistin and Reverses Colistin Resistance in Gram-Negative Bacilli [J]. Antimicrob Agents Chemother. 63(4):e02574\u201318","DOI":"10.1128\/AAC.02574-18"},{"key":"4646_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.676414","volume":"12","author":"X Feng","year":"2021","unstructured":"Feng X, Liu S, Wang Y et al (2021) Synergistic activity of colistin combined with auranofin against colistin-resistant Gram-negative bacteria. Front Microbiol 12:676414","journal-title":"Front Microbiol"},{"issue":"10","key":"4646_CR31","first-page":"1206","volume":"23","author":"LG Bian","year":"2024","unstructured":"Bian LG, J H, Juan (2024) Comparison of in vitro and in vivo antimicrobial activity of ceftazidime\/avibactam alone or in combination with Aztreonam against carbapenem-resistant Enterobacterales[J]. J Infect 23(10):1206\u20131212","journal-title":"J Infect"},{"issue":"21","key":"4646_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232113483","volume":"23","author":"J Admella","year":"2022","unstructured":"Admella J, Torrents E (2022) A straightforward method for the isolation and cultivation of Galleria mellonella hemocytes. Int J Mol Sci 23(21):13483","journal-title":"Int J Mol Sci"},{"key":"4646_CR33","doi-asserted-by":"crossref","unstructured":"Ramarao N, Nielsen-Leroux C, Lereclus D (2012) The insect Galleria mellonella as a powerful infection model to investigate bacterial pathogenesis [J]. J Vis Exp. (70):e4392","DOI":"10.3791\/4392"},{"key":"4646_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.757470","volume":"11","author":"X Han","year":"2021","unstructured":"Han X, Shi Q, Mao Y et al (2021) Emergence of ceftazidime\/avibactam and tigecycline resistance in carbapenem-resistant Klebsiella pneumoniae due to in-host microevolution. Front Cell Infect Microbiol 11:757470","journal-title":"Front Cell Infect Microbiol"},{"key":"4646_CR35","doi-asserted-by":"publisher","first-page":"772372","DOI":"10.3389\/fmed.2022.772372","volume":"9","author":"K Chang","year":"2022","unstructured":"Chang K, Wang H, Zhao J et al (2022) Polymyxin B\/Tigecycline combination vs. Polymyxin B or Tigecycline alone for the treatment of Hospital-Acquired pneumonia caused by Carbapenem-Resistant Enterobacteriaceae or Carbapenem-Resistant Acinetobacter baumannii[J]. Front Med (Lausanne) 9:772372","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"4646_CR36","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1089\/mdr.2018.0234","volume":"25","author":"D Ojdana","year":"2019","unstructured":"Ojdana D, Gutowska A, Sacha P et al (2019) Activity of ceftazidime-avibactam alone and in combination with ertapenem, fosfomycin, and tigecycline against carbapenemase-producing Klebsiella pneumoniae. Microb Drug Resist 25(9):1357\u20131364","journal-title":"Microb Drug Resist"},{"key":"4646_CR37","doi-asserted-by":"crossref","unstructured":"Shields RK, Nguyen MH, Hao B et al (2018) Colistin does not potentiate Ceftazidime-Avibactam killing of Carbapenem-Resistant Enterobacteriaceae in vitro or suppress emergence of Ceftazidime-Avibactam Resistance[J]. Antimicrob Agents Chemother,62(8):e01018-18","DOI":"10.1128\/AAC.01018-18"},{"issue":"4","key":"4646_CR38","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/jac\/dkaa531","volume":"76","author":"A Bhatnagar","year":"2021","unstructured":"Bhatnagar A, Ransom EM, Machado MJ et al (2021) Assessing the in vitro impact of ceftazidime on aztreonam\/avibactam susceptibility testing for highly resistant MBL-producing Enterobacterales. J Antimicrob Chemother 76(4):979\u2013983","journal-title":"J Antimicrob Chemother"},{"key":"4646_CR39","doi-asserted-by":"publisher","first-page":"1210313","DOI":"10.3389\/fmicb.2024.1210313","volume":"15","author":"X Li","year":"2024","unstructured":"Li X, Zhang J, Wang J et al (2024) Activities of Aztreonam in combination with several novel beta-lactam-beta-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniae strains coproducing KPC and NDM[J]. Front Microbiol 15:1210313","journal-title":"Front Microbiol"},{"key":"4646_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/srep22571","volume":"6","author":"S Thangamani","year":"2016","unstructured":"Thangamani S, Mohammad H, Abushahba MF et al (2016) Antibacterial activity and mechanism of action of auranofin against multi-drug resistant bacterial pathogens. Sci Rep 6:22571","journal-title":"Sci Rep"},{"issue":"1","key":"4646_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2024.116413","volume":"110","author":"D Lee","year":"2024","unstructured":"Lee D, Eom Y (2024) Auranofin enhances the antibacterial effects of ertapenem against carbapenem-resistant Escherichia coli. Diagn Microbiol Infect Dis 110(1):116413","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"5","key":"4646_CR42","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1093\/jac\/dkae074","volume":"79","author":"M Zheng","year":"2024","unstructured":"Zheng M, Li F, Liu J et al (2024) Synergistic effects of ceftazidime\/avibactam combined with meropenem in a murine model of infection with KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother 79(5):1069\u20131080","journal-title":"J Antimicrob Chemother"},{"key":"4646_CR43","doi-asserted-by":"crossref","unstructured":"Palwe S, Bakthavatchalam YD, Khobragadea K et al In-Vitro Selection of Ceftazidime\/Avibactam Resistance in OXA-48-Like-Expressing Klebsiella pneumoniae: In-Vitro and In-Vivo Fitness, Genetic Basis and Activities of beta-Lactam Plus Novel beta-Lactamase Inhibitor or beta-Lactam Enhancer Combinations[J]. Antibiotics (Basel), 2021,10(11)","DOI":"10.3390\/antibiotics10111318"}],"container-title":["Current Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-025-04646-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00284-025-04646-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-025-04646-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T13:15:34Z","timestamp":1770383734000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00284-025-04646-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4646"],"URL":"https:\/\/doi.org\/10.1007\/s00284-025-04646-8","relation":{},"ISSN":["0343-8651","1432-0991"],"issn-type":[{"value":"0343-8651","type":"print"},{"value":"1432-0991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"21 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"None to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Transparency Declarations"}},{"value":"The study was approved by the Clinical Trial Ethics Committee and Animal Ethics Committee of Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University (No. 2022DZGZR-086 and 2022DZGKJDWLS-0012).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}],"article-number":"66"}}